Predict your next investment

Venture Capital
pontifax.com

See what CB Insights has to offer

Investments

111

Portfolio Exits

20

Funds

7

About Pontifax

Pontifax, founded in 2004, is an Israeli venture capital firm specializing in investments in incubation, seed or startups, early, and mid stage in the life sciences sector. The firm seeks to invest in companies based in Israel.

Pontifax Headquarter Location

14 Shenkar St.

Herzliya,

Israel

+972 9 9725617

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Pontifax

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Find Pontifax in 1 Expert Collection, including Synthetic Biology.

S

Synthetic Biology

382 items

Latest Pontifax News

Armgo Pharma Raises $35M in Funding

Jan 3, 2022

Armgo Pharma, an Ardsley, New York-based novel small molecule therapeutics company developing treatments for cardiac, musculoskeletal, and neurological disorders, closed a $35m financing round. The round was led by Forbion with participation from Pontifax and Kurma Partners. In conjunction with the funding, Dr. Geert-Jan Mulder and Dr. Dmitrij Hristodorov from Forbion, Dr. Iyona Rajkomar from Pontifax and Dr. Peter Neubeck from Kurma will join Armgo’s Board of Directors. Proceeds will fund further clinical development of its lead asset, ARM210, for the treatment of catecholaminergic polymorphic ventricular tachycardia (CPVT) as well as other cardiac and skeletal muscle indications. Led by Gene Marcantonio MD PhD, President and Chief Medical Officer, Armgo Pharma is a biopharmaceutical company dedicated to applying original, targeted science to the discovery and development of novel small-molecule therapeutics to treat debilitating cardiac, musculoskeletal, and neurological disorders. The company’s proprietary drugs, known as Rycals®, are a new class of oral agents that repair calcium leaks through the RyR. Armgo Pharma has been awarded an exclusive, worldwide license from Columbia University for its RyR technology based on the research of founding scientist Andrew R. Marks, M.D. The investment will fund Phase 2 clinical studies, commencing later this year, to evaluate ARM210 for the treatment of CPVT, a rare form of ventricular tachycardia and sudden death caused by mutations in the ryanodine receptor 2 (RyR2) which controls Ca2+ homeostasis in cells. FinSMEs

Pontifax Investments

111 Investments

Pontifax has made 111 investments. Their latest investment was in Precirix as part of their Series B on March 3, 2022.

CBI Logo

Pontifax Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

3/16/2022

Series B

Precirix

$87.92M

No

7

12/20/2021

Series B

Armgo Pharma

$35M

Yes

6

12/16/2021

Series B

Anaveon

$119.36M

Yes

7

12/7/2021

Series A

Subscribe to see more

$99M

Subscribe to see more

10

11/15/2021

Series A

Subscribe to see more

$99M

Subscribe to see more

10

Date

3/16/2022

12/20/2021

12/16/2021

12/7/2021

11/15/2021

Round

Series B

Series B

Series B

Series A

Series A

Company

Precirix

Armgo Pharma

Anaveon

Subscribe to see more

Subscribe to see more

Amount

$87.92M

$35M

$119.36M

$99M

$99M

New?

No

Yes

Yes

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

7

6

7

10

10

Pontifax Portfolio Exits

20 Portfolio Exits

Pontifax has 20 portfolio exits. Their latest portfolio exit was Theseus Pharmaceuticals on October 07, 2021.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

10/7/2021

IPO

11

7/23/2021

IPO

$99M

10

12/4/2020

IPO

$99M

2

4/29/2020

Reverse Merger

Subscribe to see more

Subscribe to see more

10

4/8/2020

IPO

Subscribe to see more

$99M

Subscribe to see more

10

Date

10/7/2021

7/23/2021

12/4/2020

4/29/2020

4/8/2020

Exit

IPO

IPO

IPO

Reverse Merger

IPO

Companies

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

Acquirer

Subscribe to see more

Subscribe to see more

Sources

11

10

2

10

10

Pontifax Fund History

7 Fund Histories

Pontifax has 7 funds, including Pontifax Global Food & Agriculture Technology Fund II LP.

Closing Date

Fund

Fund Type

Status

Amount

Sources

10/18/2019

Pontifax Global Food & Agriculture Technology Fund II LP

Late-Stage Venture Capital

Open

$140M

1

11/22/2018

Pontifax Fund VI

$99M

10

1/1/2018

Pontifax Fund V

$99M

10

10/11/2017

Pontifax AgTech Fund

Subscribe to see more

Subscribe to see more

$99M

10

11/2/2011

Pontifax III

Subscribe to see more

Subscribe to see more

$99M

10

Closing Date

10/18/2019

11/22/2018

1/1/2018

10/11/2017

11/2/2011

Fund

Pontifax Global Food & Agriculture Technology Fund II LP

Pontifax Fund VI

Pontifax Fund V

Pontifax AgTech Fund

Pontifax III

Fund Type

Late-Stage Venture Capital

Subscribe to see more

Subscribe to see more

Status

Open

Subscribe to see more

Subscribe to see more

Amount

$140M

$99M

$99M

$99M

$99M

Sources

1

10

10

10

10

Pontifax Team

4 Team Members

Pontifax has 4 team members, including current Founder, Chief Executive Officer, Owner, Kariv Tomer.

Name

Work History

Title

Status

Eli Hurvitz

Founder

Current

Tomer Kariv

S.R. Group

Founder

Current

Kariv Tomer

Founder, Chief Executive Officer, Owner

Current

Philip Erlanger

Managing Partner

Current

Name

Eli Hurvitz

Tomer Kariv

Kariv Tomer

Philip Erlanger

Work History

S.R. Group

Title

Founder

Founder

Founder, Chief Executive Officer, Owner

Managing Partner

Status

Current

Current

Current

Current

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.